FDA Approval Summary: Nalmefene Nasal Spray for the Emergency Treatment of Known or Suspected Opioid Overdose
Clinical Pharmacology & Therapeutics · 2025
DOI: 10.1002/cpt.3514 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Pharmacology & Therapeutics, 2025. Verfasst von Srikanth C Nallani und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Neuropsychiatric Pharmacology, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research…. Hauptthemen laut MEDLINE: Naltrexone, Narcotic Antagonists, Opiate Overdose. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 19 Literaturangaben.
Abstract (Originalsprache)
On May 22, 2023, the United States Food and Drug Administration approved the first nalmefene hydrochloride nasal spray for the emergency treatment of known or suspected opioid overdose in adults and pediatric patients 12 years of age and older. This approval of a new prescription nalmefene hydrochloride nasal spray adds to the available opioid reversal options for hospitals, communities, harm reduction groups, and emergency responders. Due to the life‐threatening nature of opioid overdose, conducting randomized, well‐controlled clinical efficacy trials in the target patient population is neither ethical nor feasible. Clinical investigations of nalmefene nasal spray consisted of two pharmacokinetic studies and one pharmacodynamic study. Approval of the new drug application was based on the scientific bridge established by the two pharmacokinetic studies to the Agency's previous efficacy and safety findings for the listed drug nalmefene hydrochloride injection. Additionally, the pharmacodynamic study conducted in an opioid‐induced respiratory depression model in healthy volunteers established the onset of action of nalmefene administered as a nasal spray. A high‐level summary of regulatory and scientific considerations during the development and approval of nalmefene nasal spray are presented.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Neuropsychiatric Pharmacology, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.
- Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.
- Division of Anesthesiology, Addiction Medicine, and Pain Medicine, Office of New Drugs, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.
ORCID-Profile: Srikanth C Nallani, Zhihua Li
Zitieren
APA
Nallani, S. C., Li, Z., Florian, J., Xu, Y., Sabarinath, S., Brescia-Oddo, T., Roca, R. A., Uppoor, R. S., & Mehta, M. U. (2025). FDA Approval Summary: Nalmefene Nasal Spray for the Emergency Treatment of Known or Suspected Opioid Overdose. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.3514
Vancouver
Nallani SC, Li Z, Florian J, Xu Y, Sabarinath S, Brescia-Oddo T, et al. FDA Approval Summary: Nalmefene Nasal Spray for the Emergency Treatment of Known or Suspected Opioid Overdose. Clinical Pharmacology & Therapeutics. 2025. doi:10.1002/cpt.3514
BibTeX
@article{Nallani2025,
author = {Nallani, Srikanth C and Li, Zhihua and Florian, Jeffry and Xu, Yun and Sabarinath, Sreedharan and Brescia-Oddo, Tanya and Roca, Rigoberto A and Uppoor, Ramana S and Mehta, Mehul U},
title = {FDA Approval Summary: Nalmefene Nasal Spray for the Emergency Treatment of Known or Suspected Opioid Overdose},
journal = {Clinical Pharmacology & Therapeutics},
year = {2025},
doi = {10.1002/cpt.3514}
}
EUVIMED